Tissue factor associates with survival and regulates tumour progression in osteosarcoma

Tieken, Chris; Verboom, Michiel C.; Ruf, Wolfram; Gelderblom, Hans; Bovée, Judith V.M.G.; Reitsma, Pieter H.; Cleton‐Jansen, Anne‐Marie; Versteeg, Henri H.

doi:10.1160/th15-07-0541

Cited by 26 publications

(25 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was recently reported that inhibition of TF could blunt osteosarcoma progression [7], and patients with ovarian cancer, who had high expression of TF, demonstrated poor prognosis as compared with those with a low TF expression [8]. Similar findings were also reported in breast cancer, prostate cancer and pancreatic cancer [9][10][11][12].…”

Section: Ivyspringsupporting

confidence: 65%

Down-regulation of tissue factor inhibits invasion and metastasis of non-small cell lung cancer

Xia¹,

Zhang²,

Chen³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Objective: Tissue factor (TF) is clinically identified as a marker for the detection of various types of cancer as well as the prediction of prognosis for cancer patients. This present study aims to explore the possibility and feasibility to use plasma TF as a biomarker for the prediction of prognosis of patients with non-small cell lung cancer (NSCLC). Methods: A total of 100 patients with NSCLC at stage I to IV was included in the study, in whom the expression of plasma TF was detected. The Cox proportional-hazards regression model was then used to analyze the collected information, attempting to identify how patients' overall survival (OS) was associated with the expression of plasma TF. To verify the function of TF in invasion and metastasis, the expression of plasma TF was downregulated by SiRNA both in vivo and in vitro. Results: The expression of plasma TF in NSCLC patients was related to the diagnosis age of the patient. It was noted that patients with high TF expression levels tended to have worse OS performance, which implied that TF could be used as a marker for patients with stage I-IV NSCLC (HR = 2.030, 95% CI = 1.21-3.398, P = 0.007). TF down-regulation inhibited the growth of tumor in vitro as well as the metastasis and invasion of NSCLC cells in vivo. Conclusion: Both in vivo and in vitro, the invasion and migration of NSCLC cells are suppressed by TF knockdown. TF has the potential to become an effective biomarker for the prediction of prognosis of patients with stage I-IV NSCLC.

show abstract

Section: Ivyspringsupporting

confidence: 65%

Down-regulation of tissue factor inhibits invasion and metastasis of non-small cell lung cancer

Xia¹,

Zhang²,

Chen³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Кроме этого, в литературе существует достаточно доказательств, что TF стимулирует миграцию клеток посредством активации рецептора PAR2 [80][81][82][83].…”

Section: фундаментальные исследования в практической медицине на соврunclassified

The role of tissue factor in metastasising, neoangiogenesis and hemostasis in cancer

2019

View full text Add to dashboard Cite

Tissue factor, being the main initiator of the blood coagulation in vivo, is involved in a number of physiological processes, such as angiogenesis or cell migration. These processes are not only significant for normal physiology, but also play a role in the development and progression of oncological diseases. This review presents data on the structure of tissue factor, its expression in normal conditions and in cancer, its role in thrombosis development associated with cancer, in angiogenesis and in metastasis. The involvement of tissue factor in such a wide range of physiological processes important for the progression of cancer makes it an attractive target molecule for therapy.

show abstract

“…The resulting activated FVII (FVIIa) forms a complex with TF (TF:FVIIa), triggering the blood coagulation cascade [2, 3]. Many tumor types express TF, with increased expression correlating with tumor invasiveness and worsened prognosis [4-6]. TF:FVIIa may contribute to tumor invasiveness by promoting cell migration through upregulation of chemokines such as interleukin-8 and by inducing angiogenesis through vascular endothelial growth factor signaling [7, 8].…”

Section: Introductionmentioning

confidence: 99%

A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer

Ramanathan¹,

Thomas²,

Khorana³

et al. 2019

Oncology

View full text Add to dashboard Cite

Objectives: Tissue factor overexpression is associated with tumor progression, venous thromboembolism, and worsened survival in patients with cancer. Tissue factor and activated factor VII (FVIIa) complex may contribute to tumor invasiveness by promoting cell migration and angiogenesis. The study objective was to evaluate safety, pharmacokinetics, and efficacy of PCI-27483, a selective FVIIa inhibitor. Methods: This was an open-label, multicenter phase 2 trial of patients with advanced pancreatic cancer. Part A of the study was an intrapatient dose escalation lead-in portion in patients concurrently receiving gemcitabine, and in part B, patients were randomized 1: 1 to the recommended phase 2 dose combination PCI-27483–gemcitabine versus gemcitabine alone. Results: Target international normalized ratio (between 2.0–3.0) was achieved following PCI-27483 treatment. Overall safety of PCI-27483–gemcitabine (n = 26) was similar to gemcitabine alone (n = 16), with a higher incidence of mostly low-grade bleeding events (65% vs. 19%). Progression-free survival (PFS) and overall survival (OS) were not significantly different between patients treated with PCI-27483–gemcitabine (PFS: 3.7 months, OS: 5.7 months) and those treated with gemcitabine alone (PFS: 1.9 months, OS: 5.6 months). Conclusions: Targeted inhibition of the coagulation cascade was achieved by administering PCI-27483. PCI-27483–gemcitabine was well tolerated, but superiority to single agent gemcitabine was not demonstrated.

show abstract

Tissue factor associates with survival and regulates tumour progression in osteosarcoma

Cited by 26 publications

References 43 publications

Down-regulation of tissue factor inhibits invasion and metastasis of non-small cell lung cancer

Down-regulation of tissue factor inhibits invasion and metastasis of non-small cell lung cancer

The role of tissue factor in metastasising, neoangiogenesis and hemostasis in cancer

A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer

Contact Info

Product

Resources

About